CN101632832B - Component for reducing body fat formation and application thereof - Google Patents
Component for reducing body fat formation and application thereof Download PDFInfo
- Publication number
- CN101632832B CN101632832B CN2008101340202A CN200810134020A CN101632832B CN 101632832 B CN101632832 B CN 101632832B CN 2008101340202 A CN2008101340202 A CN 2008101340202A CN 200810134020 A CN200810134020 A CN 200810134020A CN 101632832 B CN101632832 B CN 101632832B
- Authority
- CN
- China
- Prior art keywords
- chromium
- lactoferrin
- trivalent chromium
- application
- constituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a component for reducing body fat formation and application thereof. The component comprises lactoferrin and a trivalent chromium compound, wherein the trivalent chromium compound is selected from a group consisting of free chromium trichloride hexahydrate, chromium trichloride, chromium acetate, chromium sulphate, chromium picolinate, chromium nicotinate, chromium glucose tolerance factor, chromium yeast, other inorganic trivalent chromiums, other organic trivalent chromiums as well as compositions of the compounds. The component of the invention can be transferred into muscular tissues by glucoses in helper cells to be used and can reduce the transformation of the glucoses into fats for storage, thereby realizing the control of weight.
Description
Technical field
The invention relates to a kind ofly in order to reduce constituent that body fat forms and uses thereof, refer in particular to a kind of in order to reduce trivalent chromium lactoferrin constituent that body fat forms and uses thereof.
Background technology
In the result of modern science and technology, computerization and mechanization, static life style becomes a kind of trend, adds the impact of west fast food culture, and the trend of the increase of healing is arranged with obesogenous prevalence rate.The fat probability of suffering from the relevant chronic disease diabetes of metabolism, cardiovascular disease, hypertension etc. that increases not only affects the personal lifestyle quality, increases social medical burden, has also hindered national whole competitiveness.So body weight control has become the most important problem of modern's maintaining healthy.
Obesity is to cause by " adipose cell increase ", " change of adipose cell body greatly " or the mode of " adipose cell increase and adipose cell itself are also loose ".In each adipose cell, all contain triglyceride, when the triglyceride quantitative change is large, the adipose cell volume is amplification just, causes obesity; Anti-, the burning triglyceride, cellular atrophy, stature gets off with regard to thin.Under normal conditions, the adipose cell number just no longer increases after having arrived adolescence.So the people who just gets fat after growing up, generally just adipose cell causes because the storage superabundant fats becomes large institute.
Owing to being stored in fatty kenel easily, the unnecessary heat that does not consume causes obesity in the body, therefore medical circles are used for the relevant medicine of fat-reducing nothing more than being now: (1) but the medicine of appetite-suppressing, for example: Sibutramine hydrochloride (sibutramine hydrochloride monohydrate); Or the medicine of (2) obstruction nutritious compound absorption, for example: orlistat (orlistat).Yet, the medicine of appetite-suppressing and obstruction nutritious compound absorption has a little side effect to produce easily, such as: Sibutramine hydrochloride (sibutraminehydrochloride monohydrate) headache, constipation arranged easily, feel sick, the side effect such as dizzy, xerostomia and insomnia, and orlistat (orlistat) has the problem of gastrointestinal disorders easily.
Summary of the invention
The purpose of this invention is to provide a kind of health promoting product of controlling body weight and not having side effect.
Be different from general diet products solution commonly used (for example: appetite-suppressing and obstruction nutritious compound absorption), the invention provides a kind of constituent that forms in order to reduce body fat, it is utilized to muscular tissue by the glucose transport in the helper cell, and reduce conversion of glucose and become fat stores, and reach the purpose of body weight control.
For achieving the above object, the constituent that forms in order to reduce body fat provided by the invention, it comprises: lactoferrin and trivalent chromium compound.In addition, the present invention also provides the purposes of a kind of constituent aspect the formation of minimizing body fat, and this constituent comprises lactoferrin and trivalent chromium compound.
Lactoferrin in the constituent of the present invention there is no special restriction, can come from Bovine Lactoferrin, gLF, not purified Lac Bovis seu Bubali, not purified Lac caprae seu ovis or its compositions.Because lactoferrin mainly is present in milk surum (whey) part of breast, so the lactoferrin in the constituent of the present invention also can substitute with lactalbumin goods or middle fat milk powder fully or partly.
Trivalent chromium compound in the constituent of the present invention there is no special restriction, and employed trivalent chromium compound can be inorganic trivalent chromium, organic trivalent chromium or its compositions.
Inorganic trivalent chromium such as: chromic chloride hexahydrate (chromium (III) chloridehexahydrate), chromium trichloride (chromium (III) chloride), and chromic sulfate (chromium (III) sulfate) etc.
Organic trivalent chromium is for example: chromium acetate, chromium picolinate (chromium picolinate), chromium nicotinate (chromium nicotinate), amino acid chelated chromium, sugar tolerance factor chrome (chromium GTF), yeast chromium (chromium yeast extract, such as: beer yeast chromium), and chromium yeast etc.
Be preferably, trivalent chromium compound be selected from by chromic chloride hexahydrate, chromium trichloride, chromium acetate, chromic sulfate, chromium picolinate, chromium nicotinate, sugar tolerance factor chrome, yeast chromium with and group that compositions was formed.
Generally speaking, the ratio of the lactoferrin in the constituent of the present invention and trivalent chromium compound also need not limit especially.Be preferably, the molar ratio of trivalent chromium compound and lactoferrin is 1: 0.001 to 1: 10, is more preferred from 1: 0.01 to 1: 1.
Constituent of the present invention can be used as pharmaceuticals, also can be added in the milk product, to obtain containing the milk product of trivalent chromium lactoferrin constituent, be a kind of food or nutriment, the group that the sweet milk of the various mammals of the optional freedom of this milk product, guarantor's breast of a specified duration, concentrated breast, cheese and milk powder form.
In constituent of the present invention, lactoferrin is the strand glucoprotein (glycoprotein) with metal ion binding ability, and the lactoferrin of every a part can be combined with two trivalent chromic ions, forms trivalent chromium lactoferrin complex.Compared to the low absorptivity (absorbance of inorganic chromium only has 0.4% to 3%) of inorganic chromium and organic chromium, the utilization that more can effectively be absorbed by the body of the trivalent chromium lactoferrin complex in the constituent of the present invention.
Accordingly, constituent of the present invention can be taken or eat for the overweight people, regularly take or edible trivalent chromium lactoferrin constituent of the present invention, the effective deficiency of organic chromium in the added body not only, more but the glucose transport in the helper cell is utilized to muscular tissue, reduce conversion of glucose and become fat stores, be conducive to the burning of fat and construction and the repairing of muscular tissue, and then the increase of effective control volume lipogenesis and body weight.In addition, trivalent chromium lactoferrin constituent of the present invention also can improve the high body slimming element mass formed by blood stasis that the overweight people suffers from because of body slimming element impedance (leptin resistance).
The specific embodiment
The manufacturing of constituent of the present invention, it can add the trivalent chromium compound powder by the lactoferrin powder, can obtain the trivalent chromium lactoferrin constituent that contains of the present invention through stirring.In addition, can also the lactoferrin powder, the trivalent chromium compound powder adds pure water, mix and obtain mixed liquor; Heating that also can be suitable in the process that stirs, so that fully mix, heating-up temperature can in about 37 ℃ to 95 ℃ scope, be preferably at 50 ℃ to 80 ℃.With resulting spray-dried through well-mixed mixed liquor, can obtain the trivalent chromium lactoferrin constituent that contains of the present invention.
Constituent of the present invention, employed trivalent chromium raw material can be that inorganic chromium also can be organic chromium, for example chromic chloride hexahydrate, chromium trichloride, chromium acetate, chromic sulfate, chromium picolinate, chromium nicotinate, sugar tolerance factor chrome, yeast chromium or chromium yeast.
Lactoferrin source can be liquid or dry lactoferrin powder, not purified Lac Bovis seu Bubali or not purified Lac caprae seu ovis.Because lactoferrin mainly is present in the whey portion of breast, in the present invention, also can use not purified lactalbumin goods or middle fat milk powder.
For the purpose of conveniently illustrating further, will enumerate following examples and do more specific description.Following examples are of the present invention specifying, but can therefore not limit scope of the present invention.
Preparation example 1
Get lactoferrin powder (3.0 g) and add chromic chloride hexahydrate powder (0.5 g), add pure water (1 liter), mix and obtain mixed liquor, mix with fat milk powder and 100 g of lactalbumins in 196 g resulting mixed liquor is spray-dried, can obtain the trivalent chromium lactoferrin constituent that contains of the present invention.
Preparation example 2
Get lactoferrin powder (60 g) and lactalbumin (400 g) and add chromic chloride hexahydrate powder (1 g), adding 50 ℃ of pure water heating mixes and obtains mixed liquor, resulting mixed liquor is mixed with fat milk powder in 200 kilograms, spray-dried sieving can obtain the trivalent chromium lactoferrin constituent that contains of the present invention.
Preparation example 3
Get lactoferrin powder (3 g) and lactalbumin (30 g) and add chromic chloride hexahydrate powder (154.5 g), adding 50 ℃ of pure water heating mixes and obtains mixed liquor, resulting mixed liquor is mixed with fat milk powder and 25 kilograms of milk surum eggs in 50 kilograms, spray-dried sieving can obtain the trivalent chromium lactoferrin constituent that contains of the present invention.
Test example 1
The high fat diet of mice feed causes fat (DIO Rodent Purified Diet w/60%EnergyFrom Fat, TestDiet), with preparation example 1 prepared trivalent chromium milk product, sneak into the mice diet, experimental group adds trivalent chromium milk product (0.12g/kg BW/day contains trivalent chromium 40ug/kgBW/day), and matched group does not add the trivalent chromium milk product, the male C57BL/6JNarl mice in ages in feed 8 week continues eight weeks of supplementary feeding.Note down weekly the test mice body weight change, the result is as shown in table 1.
Feed contains the experimental mice of chromic milk product, and its body weight namely significantly is lower than the control group mice of not adding the trivalent chromium milk product from the 1st week, and the result shows that the body weight of experimental group obtains effectively control.
Table 1 Mouse Weight change list (unit: g)
*Expression is remarkable with the matched group comparing difference, P＜0.05,
*Be P＜0.01;
N represents the mice number of elements.
Test example 2
The high fat diet of mice feed causes fat (DIO Rodent Purified Diet w/60%EnergyFrom Fat, TestDiet), with preparation example 1 prepared trivalent chromium milk product, sneak into the mice diet, experimental group adds trivalent chromium milk product (0.12g/kg BW/day, contain trivalent chromium 40ug/kgBW/day), matched group does not add the trivalent chromium milk product, the male C57BL/6JNarl mice in ages in feed 8 week, feed was sacrificed after 8 weeks, weigh Qi Fu Testis fat and the kidney weight of fat on every side, assess its body fat fat and change, as shown in table 2.Fatty weight significantly reduced around table 2 result showed experimental group Fu Testis fat and kidney, and this expression trivalent chromium milk product has the effect that reduces body fat formation.
Table 2
*Expression is remarkable with the matched group comparing difference, P＜0.01,
* *Be P＜0.001;
N represents the mice number of elements.
Test example 3
The high fat diet of mice feed causes fat (DIO Rodent Purified Diet w/60%EnergyFrom Fat, TestDiet), with preparation example 1 prepared trivalent chromium milk product, sneak into the mice diet, experimental group adds trivalent chromium milk product (0.12g/kg BW/day, contain trivalent chromium 40ug/kgBW/day), matched group does not add the trivalent chromium milk product, the male C57BL/6JNarl mice in ages in feed 8 week, feed was sacrificed after 8 weeks, survey the content of body slimming element (leptin) in its blood, as shown in table 3.Table 3 result shows that the content of body slimming element in the experimental group blood significantly reduces, and this expression trivalent chromium milk product tool improves the effect of high body slimming element mass formed by blood stasis.
Table 3
* *Expression is remarkable with the matched group comparing difference, P＜0.001;
N represents the mice number of elements.
Test example 4
The high fat diet of mice feed causes fat (DIO Rodent Purified Diet w/60%EnergyFrom Fat, TestDiet), to prepare 1 prepared trivalent chromium milk product, sneak into the mice diet, experimental group adds trivalent chromium milk product (0.12g/kg BW/day, contain trivalent chromium 40ug/kg BW/day), matched group does not add the trivalent chromium milk product, the male C57BL/6JNarl mice in ages in feed 8 week, feed was sacrificed after 8 weeks, its Fen Fu Testis fat is fixed through formalin, paraffin embedding, section is through hematoxylin and Yihong dyeing, 100 times of microscopies, respectively under 5 different visuals field, random choose is totally 50 adipose cells in each section, measure its cell dia, represent the size of this mice adipose cell with its meansigma methods.The result shows that the control group mice adipose cell is larger because being full of the fat drop cell; Yet after the trivalent chromium milk product replenished, experimental group significantly reduced the size of adipose cell, shows such as table 4.
Table 4 (unit: μ m)
*Expression is remarkable with the matched group comparing difference, P＜0.01;
N represents the mice number of elements.
Through aforementioned table 1, table 2, table 3 and table 4 proof, take the milk product that contains constituent of the present invention, really can effectively control the formation of body weight and body fat.Wherein, the per kilogram of body weight mice takes contain the Cr that has an appointment every day
+ 3The trivalent chromium lactoferrin constituent of 40 μ g can reach the effect that remarkable minimizing body fat formed and controlled body weight.Accordingly, can be regarded as according to receptor metabolic rate ratio, the trivalent chromium that contains in the trivalent chromium lactoferrin constituent of taking the human every day of per kilogram of body weight at least about 4 μ g also can have significant minimizing body fat to form effect (human metabolic rate is 1/10 times of mice).
Test example 5
The high fat diet of C57BL/6JNarl mice (N=70) feed (high-fat Rodent TestDiet, PMI Nutrition International Inc., MO, U.S.A.; 67%of calories provided byfat), respectively with lactoferrin (NZMP lactoferrin, New Zealand, low dosage 40mg/kgBW/day, high dose 80mg/kgBW/day), (with the chromic chloride hexahydrate configuration, low dosage contains Cr to trivalent chromium
+ 340 μ g/kgBW/day, high dose contains Cr
+ 380 μ g/kgBW/day), reach lactoferrin/trivalent chromium constituent (low dosage: lactoferrin 40mg/kgBW/day+Cr
+ 340 μ g/kgBW/day, high dose: lactoferrin 80mg/kgBW/day+Cr
+ 380 μ g/kgBW/day) sneak into the mice diet, matched group does not then add, and mice is divided into into seven groups, and 10 every group, the male C57BL/6JNarl mice in ages in feed 8 week is sacrificed after 7 weeks through feed, surveys Qi Fu Testis fat and heavily reaches body weight, and its result is as shown in table 5 below.
Table 5
*Expression is remarkable with the matched group comparing difference, P＜0.05;
* *Be P＜0.001.
Table 5 result shows that it is larger that control group mice Fu Testis fat heavily reaches body weight; Yet after trivalent chromium lactoferrin constituent replenished, Qi Fu Testis fat heavily reaches body weight significantly to be reduced, and gives separately lactoferrin or trivalent chromium without remarkable effect.Hence one can see that, and compared to independent lactoferrin or trivalent chromium, trivalent chromium lactoferrin constituent has significantly better effect.
In sum, the trivalent chromium lactoferrin constituent that contains of the present invention can for fat highrisk populations or the patient takes or edible, to downgrade body fat and body weight, reduces the size of adipose cell, and improves high body slimming element mass formed by blood stasis, to reach the purpose of control body weight.
Above-described embodiment is only given an example for convenience of description, and the interest field that the present invention advocates is from should with described being as the criterion of claim scope of application, but not only limiting to above-described embodiment.
Claims (6)
1. the application of following constituent in preparation minimizing body fat formation medicine, this constituent comprises lactoferrin and trivalent chromium compound, this trivalent chromium compound be selected from by chromic chloride hexahydrate, chromium trichloride, chromium acetate, chromic sulfate, chromium picolinate, chromium nicotinate, sugar tolerance factor chrome, yeast chromium with and group that compositions was formed.
2. application as claimed in claim 1, wherein, the molar ratio of this trivalent chromium compound and this lactoferrin is 1: 0.001 to 1: 10.
3. application as claimed in claim 1, wherein, the molar ratio of this trivalent chromium compound and this lactoferrin is 1: 0.01 to 1: 1.
4. application as claimed in claim 1, wherein, this lactoferrin comes from not purified breast or lactalbumin.
5. application as claimed in claim 1, wherein, this lactoferrin comes from Bovine Lactoferrin, gLF, not purified Lac Bovis seu Bubali, not purified Lac caprae seu ovis or its compositions.
6. application as claimed in claim 1, wherein, the constituent that this minimizing body fat forms is for making an addition in the milk product, and this milk product is selected from by the sweet milks of various mammals, protects the group that for a long time breast, concentrated breast, cheese and milk powder form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101340202A CN101632832B (en) | 2008-07-22 | 2008-07-22 | Component for reducing body fat formation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101340202A CN101632832B (en) | 2008-07-22 | 2008-07-22 | Component for reducing body fat formation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101632832A CN101632832A (en) | 2010-01-27 |
| CN101632832B true CN101632832B (en) | 2013-02-06 |
Family
ID=41592267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101340202A Active CN101632832B (en) | 2008-07-22 | 2008-07-22 | Component for reducing body fat formation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101632832B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3379946A1 (en) * | 2015-11-27 | 2018-10-03 | DoubleGood AB | Food supplement and composition for treating the metabolic syndrome |
| CN111904978A (en) * | 2019-05-08 | 2020-11-10 | 加特福生物科技股份有限公司 | Composition for promoting lipid metabolism or aiding weight control |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060030519A1 (en) * | 2004-08-05 | 2006-02-09 | Maxluck Biotechnology Corp. | Composition for reducing blood lipids |
| CN1736478A (en) * | 2004-08-17 | 2006-02-22 | 加特福生物科技股份有限公司 | Composition for lowering blood fat |
| CN1899606A (en) * | 2005-07-19 | 2007-01-24 | 加特福生物科技股份有限公司 | Component for preventing and controlling heart diseases |
-
2008
- 2008-07-22 CN CN2008101340202A patent/CN101632832B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060030519A1 (en) * | 2004-08-05 | 2006-02-09 | Maxluck Biotechnology Corp. | Composition for reducing blood lipids |
| CN1736478A (en) * | 2004-08-17 | 2006-02-22 | 加特福生物科技股份有限公司 | Composition for lowering blood fat |
| CN1899606A (en) * | 2005-07-19 | 2007-01-24 | 加特福生物科技股份有限公司 | Component for preventing and controlling heart diseases |
Non-Patent Citations (2)
| Title |
|---|
| 王舒然等.葡萄糖酸铬对肥胖大鼠的影响.《中国公共卫生》.2001,第17卷(第6期),515－516. * |
| 陈世伟等.吡啶酸铬对肥胖大鼠体重及其脂质代谢的影响.《中国预防医学杂志》.2004,第5卷(第1期),24-26. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101632832A (en) | 2010-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104431770B (en) | High-fiber high-protein noodles for diabetes patient and overweight person | |
| CN103889249B (en) | Use of whey protein micelles for enhancing energy expenditure and satiety | |
| CN107114798A (en) | In a kind of generation for loss of weight, eats nutrition bar and preparation method thereof | |
| CN102742737A (en) | Selenium-rich total mixed ration for fattening sheep, and production method thereof | |
| Klobukowski et al. | Calcium bioavailability from dairy products and its release from food by in vitro digestion | |
| CN110892990B (en) | Probiotic and prebiotic edible composition and application thereof | |
| CN104798908A (en) | Zinc-rich formula goat milk powder and preparation method thereof | |
| CN103976219A (en) | Two-step fermentation preparation method and application of sweet fermented-rice nutrient or brewing nutrition products | |
| CN106260534A (en) | A kind of marmoset artifical compound feed | |
| CN102415447A (en) | Calcium supplement electuary for infants and preparation process thereof | |
| CN101632832B (en) | Component for reducing body fat formation and application thereof | |
| CN103535576B (en) | Meal replacement powder containing pollen | |
| CN106472670B (en) | Sports nutritional fermented milk and preparation method thereof | |
| JP2007029020A (en) | Black vinegar health food and method for producing the same | |
| AU2005202962A1 (en) | Composition for reducing blood lipids | |
| CN102613461B (en) | Rapidly beautifying and weight losing nourishment and preparation method thereof | |
| CN104799148B (en) | A kind of special microcapsules of Diabetic Nephropathy patients and preparation method thereof | |
| CN106212903A (en) | Fattening Sheep forage grass type full-valence pellet feed and preparation method thereof | |
| CN106417596A (en) | Zinc-rich yogurt and preparation method thereof | |
| CN106387340A (en) | High-zinc selenium-enriched additive for laying hen feed, laying hen feeding method and selenium-enriched high-zinc eggs | |
| CN102551029A (en) | Composite milk mineral table salt | |
| CN106036170A (en) | Chromium-rich feed for breeding meat gooses | |
| US20100009014A1 (en) | Use of composition for manufacture of medicant and method for inhibiting formation of body fat | |
| CN105265876A (en) | Wall-broken oat slimming food and production method thereof | |
| CN106387363A (en) | Iodine-enriched selenium-enriched chromium-enriched strengthening agent for eggs, as well as preparation method and use method of iodine-enriched selenium-enriched chromium-enriched strengthening agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |